Clinical bottom line
Vasa previa is a rare but potentially catastrophic obstetric condition characterized by fetal blood vessels crossing or running near the internal cervical os, unprotected by placenta or umbilical cord. Early prenatal diagnosis via targeted ultrasound screening markedly improves perinatal outcomes by enabling planned cesarean delivery prior to labor or membrane rupture. Optimal timing of delivery balances fetal maturity against the risk of vessel rupture and fetal exsanguination. Current evidence supports elective cesarean delivery between 34 and 37 weeks’ gestation after antenatal corticosteroids, with inpatient monitoring from the late second or early third trimester. Despite advances in prenatal imaging and delivery planning, management remains challenging due to limited high-quality prospective data and variability in clinical protocols.
What the evidence shows
Prenatal diagnosis of vasa previa relies primarily on transvaginal color Doppler ultrasound, which can identify aberrant fetal vessels crossing the cervix with high sensitivity and specificity (Melcer et al., 2018; Tachibana et al., 2021). Early detection allows for planned cesarean delivery before spontaneous rupture of membranes, which is associated with fetal mortality rates up to 60–100% if undiagnosed (Robinson Barrett et al., 2011).
Robinson Barrett et al. (2011) analyzed timing strategies for delivery in vasa previa and found that elective cesarean delivery at 34–35 weeks minimized fetal death while balancing risks of prematurity. Their retrospective cohort study demonstrated that delivery before labor or membrane rupture was critical to survival. This finding is supported by Melcer et al. (2018), who emphasize the importance of antenatal corticosteroids to improve neonatal outcomes when early delivery is planned.
Inpatient hospitalization from 30–32 weeks is often recommended for close fetal monitoring and timely intervention (Sinkey et al., 2016). However, the optimal timing for hospitalization and delivery remains debated. Robinson et al. (2012) highlighted that earlier delivery reduces the risk of emergency cesarean for bleeding but may increase neonatal morbidity from prematurity, underscoring the need for individualized risk assessment.
Additional imaging modalities, including three-dimensional ultrasound and MRI, may assist in complex cases but are not routinely required (Stanislavsky et al., 2011; Rao et al., 2012). Multidisciplinary planning involving obstetrics, anesthesia, and neonatology teams is essential to optimize maternal and fetal outcomes (Sinkey et al., 2016).
Caveats and uncertainty
Despite consensus on the critical role of prenatal diagnosis and planned cesarean delivery, evidence is largely based on retrospective cohorts and expert opinion due to the rarity of vasa previa. There is no randomized controlled trial data to definitively establish the best timing for delivery or hospitalization protocols. Variability in ultrasound screening practices and diagnostic criteria may lead to underdiagnosis or false positives.
The balance between risks of prematurity and hemorrhagic fetal death remains a clinical challenge, particularly in pregnancies complicated by other comorbidities. The ideal gestational age for delivery may differ based on local neonatal intensive care capabilities and patient-specific factors. Furthermore, the psychological and economic impact of prolonged hospitalization for surveillance is not well studied.
Emerging ultrasound techniques and biomarkers may improve diagnostic accuracy but require validation. The role of outpatient monitoring with home fetal surveillance technology is unexplored. Finally, standardized clinical pathways and registries could enhance evidence quality and guide management.
How this may change practice
Clinicians should maintain a high index of suspicion for vasa previa in pregnancies with risk factors such as low-lying placenta, velamentous cord insertion, multiple gestation, or assisted reproduction. Incorporation of systematic transvaginal color Doppler ultrasound screening in the mid-trimester anatomy scan for at-risk patients can facilitate early diagnosis.
Once diagnosed, multidisciplinary care planning is paramount. Elective cesarean delivery should be scheduled between 34 and 37 weeks after corticosteroid administration, with inpatient monitoring from approximately 30–32 weeks gestation to detect signs of bleeding or labor onset. Individualized decisions regarding timing should consider fetal lung maturity, local neonatal resources, and maternal preferences.
Increased awareness and education about vasa previa among obstetric providers and sonographers can reduce missed diagnoses. Development of institutional protocols incorporating evidence-based timing strategies may improve outcomes. Future research should focus on prospective studies, refining diagnostic criteria, and evaluating novel monitoring approaches.